ID   BFTC-909 pBabeAR2
AC   CVCL_YB39
SY   BFTC 909 pBabeAR2
DR   cancercelllines; CVCL_YB39
DR   Wikidata; Q93425849
RX   PubMed=23599788;
CC   Population: Chinese; Taiwan.
CC   Sequence variation: Gene fusion; HGNC; 2151; CNGB1 + HGNC; 6326; KIFC3; Name(s)=KIFC3-CNGB1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Heterozygous (from parent cell line).
CC   Transfected with: HGNC; 644; AR.
CC   Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Derived from site: In situ; Kidney, renal pelvis; UBERON=UBERON_0001224.
DI   NCIt; C7355; Renal pelvis urothelial carcinoma
DI   ORDO; Orphanet_598216; Upper tract urothelial carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1084 ! BFTC-909
SX   Male
AG   64Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 05-10-23; Version: 10
//
RX   PubMed=23599788; DOI=10.3892/ol.2013.1140;
RA   Hsieh T.-F., Chen C.-C., Yu A.-L., Ma W.-L., Zhang C.-X., Shyr C.-R.,
RA   Chang C.-S.;
RT   "Androgen receptor decreases the cytotoxic effects of chemotherapeutic
RT   drugs in upper urinary tract urothelial carcinoma cells.";
RL   Oncol. Lett. 5:1325-1330(2013).
//